Clinical analysis of 217 patients with metastatic carcinoma of bone
10.3969/j.issn.1006-5725.2017.18.023
- VernacularTitle:骨转移癌217例临床分析
- Author:
Hanlin ZHENG
1
;
Pengfei SHEN
;
Tengfei ZHU
;
Jiaxiang WU
;
Ming YAN
;
Wenguo ZHAO
Author Information
1. 华北理工大学附属医院骨科
- Keywords:
bone metastasis;
clinical characteristics;
zoledronic acid;
retrospective analysis;
skeleton-related events
- From:
The Journal of Practical Medicine
2017;33(18):3070-3074
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical characteristics of patients with metastatic carcinoma of bone. Methods The clinical data of 217 patients with metastatic carcinoma of bone was retrospectively analyzed. The clinical features were summarized,including primary tumor,age distribution,first symptom,time of onset and bone metastatic site. Visual analogue scale(VAS)was used to evaluate the difference of pain in patients with bone metastases before and after zoledronic acid treatment. Results The bone metastasis occurred more frequently in men(male:female = 1.28:1). The majority of primary tumors were lung cancer(51.61％)and breast cancer (15.67％),respectively. The peak ages of the patients with metastatic carcinoma of bone were between 50 and 70 years old. Most of the patients with metastatic carcinoma of bone initially showed varying degrees of pain ,some of the patients with dysfunction,pathological fracture,or local lumps as the initial symptoms,only a tiny minority of patients were inadvertently found. Onset time was often within 3 months ,which accountings for 54.84％. Bone metastases were mostly in the spine,pelvis,femur and ribs,and most of the bone metastases were multiple. The VAS score of 108 patients who with bone metastases pain treated by zoledronic acid was 0～4(1.31 ± 1.07),with statistically significant differences compared with pretherapy(P<0.01). Conclusion In order to reduce the pain of patients,and to improve the quality of life and prolong the survival time,bone metastases should be diagnosed early and given comprehensive treatment.
